Analgesic
Rofecoxib
search
Rofecoxib
, Vioxx
See Also
COX2 Inhibitor
Celecoxib
Precaution
Vioxx voluntarily withdrawn from market October 2004
Withdrawal due to increased risk of MI and CVA
Class
NSAID
:
COX2 Inhibitor
Similar to
Celecoxib
(
Celebrex
)
Advantages
Less gastrointestinal adverse effects than other
NSAID
s
See
NSAID Gastrointestinal Adverse Effects
Appears safe in
Aspirin
and
NSAID
-induced
Asthma
Martin-Garcia (2002) Chest 121:1812-7 [PubMed]
Dosing
Osteoarthritis
: 12.5 to 25 mg PO qd
Acute pain or
Dysmenorrhea
: 50 mg PO qd
Pharmacokinetics
Oral
Bioavailability
: 92%
Peaks: 2-3 hours (delayed by food intake)
Half life: 17 hours
Metabolized by hepatic reduction
Factors increasing serum concentrations
Age over 65 years old
Hepatic insufficiency
Efficacy
Equivalent analgesia to 50 mg Vioxx
Ibuprofen
400 mg
Naproxen
Sodium
(e.g.
Anaprox
) 550 mg
Drug Interactions
Decreased Vioxx serum concentrations
Antacid
s (decrease Vioxx serum concentrations 20%)
Rifampin
(decrease Vioxx serum concentrations 50%)
Increased concentrations of other medications
Raises serum
Methotrexate
levels 23%
Raises
Warfarin
levels - increases
ProTime
10%
Adverse Effects
See
COX-2 Inhibitor
for Nonfatal MI risk
Confirmed in larger trial and withdrawn from market
Diarrhea
Nausea
Dyspepsia
Abdominal Pain
Lower Extremity Edema
Increased
Blood Pressure
References
Daniels (1999) Clin Pharmacol Ther 65:118 [PubMed]
Ehrich (1999) Clin Pharmacol Ther 65:336 [PubMed]
Fricke (1999) Clin Pharmacol Ther 65:119 [PubMed]
(1999) Med Lett Drugs Ther 41(1056): 59-61 [PubMed]
Type your search phrase here